# Redesign Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/redesign-science

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.redesignscience.com
- Total disclosed funding: $17M
- Latest round: Seed (Dec 8, 2021)
- Investors on record: 10

## About

Redesign Science utilizes advanced biomolecular simulations through its proprietary NUVO™ technology platform, enhancing drug discovery processes for biopharmaceutical companies and research institutions globally.Founded in 2017 in New York, US, Redesign Science specializes in biomolecular simulations. The company was co-founded by David Rooklin and Haotian Li. As of December 2021, Redesign Science raised USD 10 mn in Seed funding led by Kaitai Capital, with contributions from Collaborative Fund, Preface Ventures, Third Kind Venture Capital, and ZhenFund. The total amount raised to date is USD 10 mn across 3 deals.The company specializes in advanced biomolecular simulations through its proprietary NUVO™ technology platform, which integrates physics-based molecular dynamics with generative AI. Their core offerings include the development of first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™), which address critical challenges in therapeutic efficacy and precision medicine. These products are engineered to modulate protein interactions effectively, influencing biological pathways and disease mechanisms. Primary customers include biopharmaceutical companies and research institutions engaged in drug discovery and development, with a global client base predominantly in North America, Europe, and select Asian markets.The revenue model of the company is based on B2B transactions, focusing on partnerships with pharmaceutical firms and research organizations. Clients engage through structured collaborations, which may involve multi-year agreements for access to the NUVO™ platform and its associated technologies. Transactions encompass licensing fees for proprietary TPIM™ products, as well as ongoing support and consultancy services that enhance clients' drug development processes.Following the Seed funding of USD 10 mn raised in December 2021, Redesign Science plans to utilize the funds to expand its cloud computing infrastructure and advance several core screening algorithms to scale across a diverse range of biological target classes. The company aims to enhance its offerings, potentially leading to the introduction of new products, while also targeting expansion into additional global markets to further support its growth strategy.

## Funding rounds

- Seed, Dec 8, 2021, $5M — 5Y Capital, Collaborative Fund, Acequia Capital, Notation, Refactor Capital, Third Kind Venture Capital, Preface Ventures, Hawktail
- Seed, Dec 8, 2021, $10M — Collaborative Fund, Kaitai Capital, ZhenFund, Third Kind Venture Capital, Preface Ventures
- Seed, Oct 14, 2019, $2M — 5Y Capital, Notation, Refactor Capital, Third Kind Venture Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Seed
- Notation (https://capitalatlas.ai/funds/notation) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Third Kind Venture Capital (https://capitalatlas.ai/funds/third-kind-venture-capital) — Seed
- Collaborative Fund (https://capitalatlas.ai/funds/collaborative-fund) — Seed
- Acequia Capital (https://capitalatlas.ai/funds/acequia-capital) — Seed
- Preface Ventures (https://capitalatlas.ai/funds/preface-ventures) — Seed
- Hawktail (https://capitalatlas.ai/funds/hawktail) — Seed
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Seed
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Seed